Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway

BACKGROUND: The first one-arm phase II trial aimed to evaluate and predict efficacy and safety of S-1 plus oral leucovorin (S-1/LV) as first-line chemotherapy for patients with advanced gastric cancer (AGC), using S-1 pharmacogenetic pathway approach. PATIENTS AND METHODS: A total of 39 patients ora...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Ming-ming, Zhang, Dong-sheng, Wang, Feng, Wang, Zi-xian, Yuan, Shu-qiang, Wang, Zhi-qiang, Luo, Hui-yan, Ren, Chao, Qiu, Miao-zhen, Jin, Ying, Wang, De-shen, Chen, Dong-liang, Zeng, Zhao-lei, Li, Yu-hong, He, Yang-yang, Hao, Yuan-tao, Guo, Pi, Wang, Feng-hua, Zeng, Yi-xin, Xu, Rui-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225176/
https://www.ncbi.nlm.nih.gov/pubmed/27913881
http://dx.doi.org/10.1007/s00280-016-3209-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225176/
https://www.ncbi.nlm.nih.gov/pubmed/27913881
http://dx.doi.org/10.1007/s00280-016-3209-1

Ejemplares similares